KR102902295B1 - 피라졸로피리딘 유도체 및 이의 용도 - Google Patents

피라졸로피리딘 유도체 및 이의 용도

Info

Publication number
KR102902295B1
KR102902295B1 KR1020237034868A KR20237034868A KR102902295B1 KR 102902295 B1 KR102902295 B1 KR 102902295B1 KR 1020237034868 A KR1020237034868 A KR 1020237034868A KR 20237034868 A KR20237034868 A KR 20237034868A KR 102902295 B1 KR102902295 B1 KR 102902295B1
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
compound
delete delete
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237034868A
Other languages
English (en)
Korean (ko)
Other versions
KR20230156766A (ko
Inventor
사이몬 보나치
아르티옴 세르니젠코
제니퍼 스트로카 콥
나탈리 알리시아 데일스
자네타 듀허스트
매튜 제임스 헤세
라마 제인
존 라이언 케리건
하스나인 아메드 말릭
제임스 알. 매닝
게리 오'브라이언
앤드류 더블유. 패터슨
노엘 마리-프랑스 톰슨
파멜라 이프 팅
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20230156766A publication Critical patent/KR20230156766A/ko
Application granted granted Critical
Publication of KR102902295B1 publication Critical patent/KR102902295B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237034868A 2021-03-15 2022-03-14 피라졸로피리딘 유도체 및 이의 용도 Active KR102902295B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161139P 2021-03-15 2021-03-15
US63/161,139 2021-03-15
US202163164130P 2021-03-22 2021-03-22
US63/164,130 2021-03-22
PCT/IB2022/052281 WO2022195454A1 (en) 2021-03-15 2022-03-14 Pyrazolopyridine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
KR20230156766A KR20230156766A (ko) 2023-11-14
KR102902295B1 true KR102902295B1 (ko) 2025-12-23

Family

ID=80819999

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034868A Active KR102902295B1 (ko) 2021-03-15 2022-03-14 피라졸로피리딘 유도체 및 이의 용도

Country Status (20)

Country Link
US (4) US11787785B2 (cg-RX-API-DMAC7.html)
EP (1) EP4308562A1 (cg-RX-API-DMAC7.html)
JP (2) JP7659648B2 (cg-RX-API-DMAC7.html)
KR (1) KR102902295B1 (cg-RX-API-DMAC7.html)
AU (2) AU2022239950B2 (cg-RX-API-DMAC7.html)
CA (1) CA3208951A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002726A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013486A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230486A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000188A (cg-RX-API-DMAC7.html)
EC (1) ECSP23076800A (cg-RX-API-DMAC7.html)
IL (1) IL305931A (cg-RX-API-DMAC7.html)
JO (1) JOP20230218A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023010827A (cg-RX-API-DMAC7.html)
PE (1) PE20242203A1 (cg-RX-API-DMAC7.html)
PY (1) PY2217419A (cg-RX-API-DMAC7.html)
TW (1) TWI923713B (cg-RX-API-DMAC7.html)
UY (1) UY39671A (cg-RX-API-DMAC7.html)
WO (1) WO2022195454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202307290B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021255160B2 (en) 2020-04-13 2024-02-01 Aptabio Therapeutics Inc. Pulmonary fibrosis medicine containing pyrazole derivative
EP4308559A1 (en) * 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513164A (ja) 2003-12-02 2007-05-24 セルジーン・コーポレーション 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
JP2020531498A (ja) 2017-08-23 2020-11-05 ノバルティス アーゲー 3−(1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオン誘導体及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
EP2165707A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
JP2020009513A (ja) * 2018-07-10 2020-01-16 キオクシア株式会社 メモリシステム
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR102980990B1 (ko) 2019-04-05 2026-06-25 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4100394B1 (en) 2020-02-04 2026-04-08 Stingray Therapeutics, Inc. Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
US20230089530A1 (en) 2020-02-09 2023-03-23 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513164A (ja) 2003-12-02 2007-05-24 セルジーン・コーポレーション 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物
JP2020531498A (ja) 2017-08-23 2020-11-05 ノバルティス アーゲー 3−(1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオン誘導体及びその使用
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation

Also Published As

Publication number Publication date
PE20242203A1 (es) 2024-11-19
ZA202307290B (en) 2024-09-25
JP7659648B2 (ja) 2025-04-09
TW202304900A (zh) 2023-02-01
AU2022239950B2 (en) 2024-09-12
AU2022239950A1 (en) 2023-08-31
MX2023010827A (es) 2023-09-28
CL2023002726A1 (es) 2024-04-01
BR112023018542A2 (pt) 2023-10-10
EP4308562A1 (en) 2024-01-24
US20250282762A1 (en) 2025-09-11
JP2024509981A (ja) 2024-03-05
AU2024278210A1 (en) 2025-01-02
UY39671A (es) 2022-10-31
CA3208951A1 (en) 2022-09-22
AU2024278210B2 (en) 2026-03-26
DOP2023000188A (es) 2023-11-15
PY2217419A (es) 2022-09-27
WO2022195454A1 (en) 2022-09-22
NZ802195A (en) 2025-10-31
IL305931A (en) 2023-11-01
JOP20230218A1 (ar) 2023-09-14
ECSP23076800A (es) 2023-11-30
US20250002479A1 (en) 2025-01-02
US20240158374A1 (en) 2024-05-16
US12172984B2 (en) 2024-12-24
CO2023013486A2 (es) 2023-11-10
KR20230156766A (ko) 2023-11-14
US11787785B2 (en) 2023-10-17
US12252482B2 (en) 2025-03-18
US20230108325A1 (en) 2023-04-06
TWI923713B (zh) 2026-05-01
CR20230486A (es) 2024-01-25
JP2025106341A (ja) 2025-07-15

Similar Documents

Publication Publication Date Title
EP4076650B1 (en) 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7659648B2 (ja) ピラゾロピリジン誘導体及びその使用
US12103919B2 (en) 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20250276964A1 (en) Benzisoxazole Derivatives and Uses thereof
CN116802182A (zh) 吡唑并吡啶衍生物及其用途
BR122025004894B1 (pt) Uso de derivados de pirazolopiridina, e kit
BR112023018542B1 (pt) Derivados de pirazolopiridina, e composição e combinação farmacêuticas
BR122025004894A2 (pt) Derivados de pirazolopiridina, seus usos, composição e combinação farmacêuticas, e kit
EA051403B1 (ru) Производные пиразолопиридина и пути их применения

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)